About Us
Neutralizing antibodies as a treatment
We are a company dedicated to developing neutralizing antibodies that can be used as a treatment for novel viruses. Our team is working on improving methods for rapid screening and cloning of cells that produce high-affinity antibodies for use in clinic. While developing virus-specific drugs can take long time, neutralizing antibodies can be produced relatively quickly making them an excellent first choice of treatment until the vaccine or antivirals are available.
- Human neutralizing antibodies for treatment.
- Mouse monoclonal antibodies for research.
Our Team
.
Peter Askovich
Chief Executive OfficerExpertise in Virology, Immunology, High-throughput screening, Big data analytics. Extensive experience with developing models of viral spread inhibition using peptides.
Jeff Hogan
Chief Financial OfficerExtensive expertise in viral and bacterial immunology, vaccine development, and therapeutics including years of experience with SARS-CoV.
Tor Stuge
Chief Operating OfficerExpertise in immunology, cellular cloning, and monoclonal antibody technology, including isolation of a human monoclonal antibody pending clinical trials.
